ICG:LSEICG plc Analysis
Data as of 2026-06-13 - not real-time
£1,779.00
Latest Price
6/10Risk
Risk Level: Medium
Executive Summary
ICG plc is trading at £17.79 (GBp 1779), comfortably below its 20‑day SMA of 1,828 and 50‑day SMA of 1,800, indicating short‑term weakness, while the 30‑day RSI of 45.8 suggests the stock is neither overbought nor oversold. Technical indicators such as a bearish MACD (line –11.6, histogram –14.4) and decreasing volume reinforce a neutral‑to‑bearish near‑term outlook, though the price remains above the identified support of 1,716. On the valuation side, the forward‑looking DCF places fair value at ~2,767, implying a 35% upside from current levels, and the trailing PE of 10.8 is well below the industry average of 16.8, flagging the stock as undervalued. The dividend yield of 5.07% with a payout ratio of 51% appears sustainable given the strong cash position (≈£1.42bn) that exceeds total debt (£1.27bn). Fundamental performance is mixed: revenue fell 21.8% YoY, yet operating and profit margins remain robust around 47‑49%, and ROE sits at 18%. Recent earnings releases highlighted “strong” fee‑related earnings but disappointment in investment returns, causing a modest 1.8% share dip, underscoring short‑term pressure despite the longer‑term valuation case.
Overall, ICG offers a compelling dividend yield and attractive valuation metrics, but investors should remain cautious of the revenue decline, elevated 30‑day volatility (34%) and the current bearish technical stance. The medium‑ to long‑term thesis leans bullish, supported by a solid balance sheet, disciplined capital allocation, and a sizable upside to fair value, making the stock a potential buy for income‑focused and value‑oriented investors.
Overall, ICG offers a compelling dividend yield and attractive valuation metrics, but investors should remain cautious of the revenue decline, elevated 30‑day volatility (34%) and the current bearish technical stance. The medium‑ to long‑term thesis leans bullish, supported by a solid balance sheet, disciplined capital allocation, and a sizable upside to fair value, making the stock a potential buy for income‑focused and value‑oriented investors.
Market Outlook
Short Term
< 1 yearNeutral
Model confidence: 6/10
Key Factors
- Price below short‑term moving averages
- Bearish MACD and decreasing volume
- High dividend yield providing cushion
Medium Term
1–3 yearsPositive
Model confidence: 8/10
Key Factors
- DCF‑based upside of ~35%
- PE well below industry average
- Strong cash position and sustainable dividend
Long Term
> 3 yearsPositive
Model confidence: 9/10
Key Factors
- Undervalued relative to peers
- Robust operating margins and ROE
- Diversified global asset base supporting steady cash flows
Key Metrics & Analysis
Financial Health
Revenue Growth-21.80%
Profit Margin48.94%
P/E Ratio10.8
ROE18.44%
ROA4.97%
Debt/Equity46.98
P/B Ratio1.9
Op. Cash Flow£846.1M
Industry P/E16.8
Technical Analysis
TrendNeutral
RSI45.8
Support£1,716.00
Resistance£1,945.00
MA 20£1,827.95
MA 50£1,799.90
MA 200£1,911.40
MACDBearish
VolumeDecreasing
Fear & Greed Index89.86
Valuation
Fair Value£2,767.34
Target Price£2,410.54
Upside/Downside35.50%
GradeUndervalued
TypeValue
Dividend Yield5.07%
Risk Assessment
Beta0.78
Volatility34.28%
Sector RiskMedium
Reg. RiskMedium
Geo RiskMedium
Currency RiskMedium
Liquidity RiskMedium
Similar Tickers
This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.